

# Exploring the States



CSRO Legislative Priorities and Effective Advocacy

Saturday, September 9, 2017  
Kevin Daley  
Director of Government Affairs

# Things to Consider




- Is there a priority issue in my state?
- What advocacy tools does the CSRO have that my state can utilize?
- How can the CSRO help my state society the most?

# CSRO Year in Review



# CSRO Year in Review



CSRO Board of Director & Rheumatology Alliance of Iowa President Dr. Michael Brooks advocates for step therapy legislation during Iowa's Advocacy Day.



CSRO Board of Director & Rheumatology Association President Dr. Mark Box made the case for biological products at the Kansas State Legislature's Committee on Health and Human Services.



CSRO Board of Director Dr. Josh Stolow met with legislators in Texas to advocate for a bill that would end non-medical switching.

# CSRO Year in Review



Members from ATAP meeting with MedPAC



Dr. Feldman presents at ARA on drug pricing and transparency



Dr. Gregory Schmizzi and Dr. Madelaine Feldman present at CRA

# CSRO Year in Review



Dr. Gregory Schimizzi and Dr. Michael Schweitz at the CSRO booth at CCR 2017



2017 Fellows Conference San Francisco



Dr. Gregory Schimizzi (3rd from the left) discusses FDA guidance on biosimilars

# CSRO Year in Review



Dr. Saitta meets with Rep. Steve Womack at ASM Fly-in



CSRO & ATAP at the 2017 National Conference of State Legislatures.



ATAP Members at the first annual in-person meeting

# Priority Issues



# Priority Issues



- Step Therapy
- Non-Medical Switching
- Prior Authorization
- Out-Pocket-Costs
- Biosimilar Substitution
- Drug Pricing and Transparency

# Step Therapy

- Legislation affecting the patient-physician relationship is always circulating at the state and federal level. Vigilance and cooperation is needed when it comes to legislation regulating:
  - **Step Therapy** - insurer policies that can be designed to control their own costs by making a patient fail first on cheaper medications before giving them access to their prescribed medicine





# Step Therapy



## SAIM Coalition

The State Access to Innovative Medicine (SAIM) is a diverse group of national, state and local stakeholders with the background and expertise necessary to positively impact State legislation and other public policy.


- SAIM model language passed in New York, West Virginia, Iowa, and Texas
- Non-targeted states, limited protections passed in Colorado and Arkansas
- Bills with potential carrying over in Minnesota and Maine

# Non-Medical Switching

Under Non-Medical Switching, insurance plans require patients to use a specific medication dictated by their formulary and require patients to be switched from the medication they are currently taking regardless of their clinical response.



*Switching for non-medical reasons doesn't benefit patients—it puts patients at risk.*



States targeting Non-Medical legislation

States without active non-medical switching legislation or laws

Legislation/Regulatory passed or enacted

# Non-Medical Switching

# Non-Medical Switching



The #KeepMyRx campaign seeks to raise public awareness about the benefits of medical stability and the impact on patient health of being forced by their health plans to switch medicines. The #KeepMyRx campaign promotes legislation and policies that protect patient access to the medicines their physicians prescribe.



KEEP MY RX

<http://www.keepmyrx.org>

# Biosimilar Substitution

## WHERE WE STAND


Providing access to affordable biological products and medications is important.

Because of the complexity of these medications patient safety must be the first priority.

Substitution should only occur for FDA approved “interchangeable” biologics.

Physicians should be able to order specific medications when needed and should be notified of all substitution changes as soon as possible





States targeting biosimilar substitution legislation

States without active non-medical switching legislation or laws

Legislation passed or enacted

# Biosimilar Substitution

# Drug Pricing & Transparency



The Alliance for Transparent and Affordable Prescriptions (or “ATAP”) is a coalition of patient and provider organizations functioning at both the state and national level who have joined together to address pharmacy benefit managers (PBMs) and their impact on prescription drug costs and patient access to affordable treatment.





# Effective Advocacy

**CSRO**  
COALITION OF STATE RHEUMATOLOGY ORGANIZATIONS





# Effective Advocacy



## Why Advocacy is Important to Physicians

State legislatures are considering an increasing amount of legislation of impact to our community. In response, we must be engaged at both the state and federal levels to protect our patients and their livelihood.

# Effective Advocacy


## Quality Advocacy to Bring Beneficial Change

Quality Advocacy Involves:

- Consistent Messaging
- Coordination through various groups

To Influence:

- Legislative Process
- Regulative Process
- There are many different levels that you can advocate within...



# Effective Advocacy



- Federal
  - Direct correspondence with legislators and their staff
  - Regulatory bodies, Washington D.C. Testimonials
  - Outcome Related Research
- State
  - Direct correspondence with legislators and their staff
  - Regulatory bodies
  - Outcome Related Research
  - Medical Boards, State Specialty Societies
- Local
  - County, Hospitals
  - Outcome Related Research
  - Letter writing campaigns
  - Advocate within your own practice with your own patients!

Advocacy Levels


# Effective Advocacy




## Advocating as One

- Our main objective is to correlate with government staffs and advocacy groups to provide nationwide Rheumatologists with various types of advocacy work at all levels
  - Member letters and testimonials to government officials are imperative
  - Meetings that build legislative awareness can also help build our Coalition and its effectiveness
  - Tracking Model Language's potential effectiveness within each State's Legislature

# Effective Advocacy



# Effective Advocacy



# Effective Advocacy



- Sends out Calls to Action - (Via E-blast, Website & Social Media Outlets).
- Provides letters of support to sign-on or send individually.
- Provides talking points for committee testimony and educational meetings.
- Sends out newsletters & updates to notify membership of legislative progress & opportunities.
- Generates data through membership and patient surveys to utilize for Education Purposes.
- Initiates in-person meetings or telephone calls to educate docs and legislators on issues.
- Helps in coalition building and participation within states.
- Promotes and attends Advocacy Day's (state & federal)

# Effective Advocacy

## CSRO State Society Speaker Program

- Drug Pricing and Transparency
- MACRA
- Advocacy 101
- Priority Legislation
- Federal
- Down-coding



# Annual State Society Leadership Meeting



You're invited to join the CSRO Board of Directors to learn about the targeted issues in your state in preparation for the 2018 legislative sessions.

- When: Monday, November 6, 2017
- Time: 8:00 am - 9:00 am
- Where: Marriott Marquis San Diego Marina - La Costa Room

**\*Breakfast Provided**

# Questions?



Kevin Daley  
Director, Government Affairs  
kevin@wjweiser.com

Barbara Arango  
Associate Director  
barbara@wjweiser.com

Ally Lopshire, JD  
Government Affairs Specialist  
ally@wjweiser.com

Brian Henderson  
Government Affairs Specialist  
brian@wjweiser.com

